Navidea Biopharmaceuticals, Inc. today announced the receipt of a notice from the NYSE American LLC on January 28, 2019 that the NYSE American has granted the Company an extension until March 31, 2019 to regain compliance with Section 1003 of the NYSE American’s continued listing standards.
February 1, 2019
· 4 min read